The Risk of Posterior Reversible Encephalopathy Syndrome with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases

被引：0
|
作者：
Velez, L. [1 ]
Das, A. [2 ]
Saxena, A. [2 ]
Parulekar, V. [3 ]
Chhabra, N. [3 ]
Izquierdo, M. [4 ]
Zeeuw, P. D. [5 ]
Schaart, E. [6 ]
Eisinger, J. [5 ]
机构：
[1] Univ Basel, Patient Safety, Pharmacoepidemiol Unit, Novartis AG, Zurich, Switzerland
[2] Novartis, Signal Detect, Hyderabad, India
[3] Novartis, Patient Safety, Hyderabad, India
[4] Novartis, Clin Dev, Basel, Switzerland
[5] Novartis, Patient Safety, Basel, Switzerland
[6] Novartis, Patient Safety, E Hanover, NJ USA
来源：
DRUG SAFETY | 2022年 / 45卷 / 10期
关键词：
SIGNAL-DETECTION;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
P268
引用
收藏
页码：1250 / 1251
页数：2
相关论文
共 50 条
  • [21] Should Calcineurin Inhibitors/Sirolimus Be Ceased Completely In Posterior Reversible Encephalopathy Syndrome?
    Karatas, Cihan
    Akyollu, Basak
    Arpali, Emre
    Kocak, Burak
    TRANSPLANTATION PROCEEDINGS, 2024, 56 (01) : 93 - 96
  • [22] Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database
    Igawa, Yusuke
    Hamano, Hirofumi
    Esumi, Satoru
    Takeda, Tatsuaki
    Kajizono, Makoto
    Kikuoka, Ryo
    Kimura, Ikuya
    Zamami, Yoshito
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [23] Prevalence and risk factors of posterior reversible encephalopathy syndrome in Isfahan, Iran
    Ansari, Behnaz
    Saadatnia, Mohammad
    ADVANCED BIOMEDICAL RESEARCH, 2021, 10 (01): : 53
  • [24] POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME MARKEDLY INCREASES THE RISK OF MATERNAL MORBIDITY
    Bissing, David
    Tung, Avery
    Choi, Vivian
    Boshara, Arianna
    Dreixler, John
    Shahul, Sajid
    CRITICAL CARE MEDICINE, 2020, 48
  • [25] Posterior Reversible Encephalopathy Syndrome Markedly Increases the Risk of Maternal Morbidity
    Bissing, David
    ANESTHESIA AND ANALGESIA, 2020, 130 : 199 - 199
  • [26] Association of posterior reversible encephalopathy syndrome with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database
    Singh, Harkarandeep
    Kaur, Uttamjot
    Neupane, Niraj
    Kharel, Himal
    Saeed, Hassan
    Gill, Prabhsimrat
    Shrestha, Asis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Determinants of Recovery from Severe Posterior Reversible Encephalopathy Syndrome
    Legriel, Stephane
    Schraub, Olivier
    Azoulay, Elie
    Hantson, Philippe
    Magalhaes, Eric
    Coquet, Isaline
    Bretonniere, Cedric
    Gilhodes, Olivier
    Anguel, Nadia
    Megarbane, Bruno
    Benayoun, Laurent
    Schnell, David
    Plantefeve, Gaetan
    Charpentier, Julien
    Argaud, Laurent
    Mourvillier, Bruno
    Galbois, Arnaud
    Chalumeau-Lemoine, Ludivine
    Rivoal, Michel
    Durand, Francois
    Geffroy, Arnaud
    Simon, Marc
    Stoclin, Annabelle
    Pallot, Jean-Louis
    Arbelot, Charlotte
    Nyunga, Martine
    Lesieur, Olivier
    Troche, Gilles
    Bruneel, Fabrice
    Cordoliani, Yves-Sebastien
    Bedos, Jean-Pierre
    Pico, Fernando
    PLOS ONE, 2012, 7 (09):
  • [28] Risk factor analysis of posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT in children
    D Zama
    R Masetti
    D M Cordelli
    F Vendemini
    L Giordano
    G Milito
    E Franzoni
    F Porta
    A Prete
    R Rondelli
    A Pession
    Bone Marrow Transplantation, 2014, 49 : 1538 - 1540
  • [29] Risk factor analysis of posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT in children
    Zama, D.
    Masetti, R.
    Cordelli, D. M.
    Vendemini, F.
    Giordano, L.
    Milito, G.
    Franzoni, E.
    Porta, F.
    Prete, A.
    Rondelli, R.
    Pession, A.
    BONE MARROW TRANSPLANTATION, 2014, 49 (12) : 1538 - 1540
  • [30] Disproportionality analysis of data from VigiBase and other global product safety databases on toxicity of iron chelating agents
    Arda, Burcu Eda
    Sipahi, Hande
    EXPERT OPINION ON DRUG SAFETY, 2024,
12345